Impact of KRAS mutational status and primary tumor location on the efficacy of aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer: An exploratory analysis in a phase II study

被引：0
|
作者：
Yamazaki, K. [1 ]
Satoh, T. [2 ]
Komatsu, Y. [3 ]
Taguchi, T. [4 ]
Sunaga, Y. [5 ]
Yoshino, T. [6 ]
机构：
[1] Shizuoka Canc Ctr, Oncol, Surg, Gastroenterol, Sunto Gun, Japan
[2] Osaka Univ, Grad Sch Med, Suita, Osaka, Japan
[3] Hokkaido Univ Hosp, Ctr Canc, Sapporo, Hokkaido, Japan
[4] Sanofi Japan, Med, Tokyo, Japan
[5] Sanofi Japan, Biostat & Programming, Tokyo, Japan
[6] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
187P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II study of ziv-aflibercept (Z) plus FOLFIRI in Japanese patients (pts) with metastatic colorectal cancer (mCRC).
    Satoh, Taroh
    Denda, Tadamichi
    Hamaguchi, Tetsuya
    Sugimoto, Naotoshi
    Ura, Takashi
    Yamazaki, Kentaro
    Fujii, Hirofumi
    Kajiwara, Takeshi
    Nakajima, Takako Eguchi
    Takahashi, Shin
    Otsu, Satoshi
    Komatsu, Yoshito
    Sasaki, Toru
    Sunaga, Yoshinori
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [2] The Metastatic Profile of Colorectal Cancer: The Interplay Between the Location of Primary Tumor and KRAS Mutational Status
    Yong, Z.
    Tan, G.
    Teo, M.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S160 - S160
  • [3] Exploratory evaluation of pharmacodynamic biomarkers and pharmacokinetics (PK) of ziv-aflibercept (Z) plus FOLFIRI in a phase II study of Japanese patients (pts) with metastatic colorectal cancer (mCRC).
    Yoshino, Takayuki
    Sugimoto, Naotoshi
    Yamazaki, Kentaro
    Kajiwara, Takeshi
    Komatsu, Yoshito
    Sasaki, Toru
    Chiron, Marielle
    Ziti-Ljajic, Samira
    Brillac, Claire
    Hamaguchi, Tetsuya
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [4] The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis
    Cao, De-Dong
    Xu, Hui-Lin
    Xu, Xi-Ming
    Ge, Wei
    ONCOTARGET, 2017, 8 (32) : 53631 - 53641
  • [5] Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer
    Hamaguchi, Tetsuya
    Denda, Tadamichi
    Kudo, Toshihiro
    Sugimoto, Naotoshi
    Ura, Takashi
    Yamazaki, Kentaro
    Fujii, Hirofumi
    Kajiwara, Takeshi
    Nakajima, Takako Eguchi
    Takahashi, Shin
    Otsu, Satoshi
    Komatsu, Yoshito
    Nagashima, Fumio
    Moriwaki, Toshikazu
    Esaki, Taito
    Sato, Takeo
    Itabashi, Michio
    Oki, Eiji
    Sasaki, Toru
    Chiron, Marielle
    Yoshino, Takayuki
    CANCER SCIENCE, 2019, 110 (11) : 3565 - 3572
  • [6] A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer
    Yoshino, Takayuki
    Yamazaki, Kentaro
    Yamaguchi, Kensei
    Doi, Toshihiko
    Boku, Narikazu
    Machida, Nozomu
    Onozawa, Yusuke
    Asayama, Masako
    Fujino, Tadahiro
    Ohtsu, Atsushi
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (04) : 910 - 917
  • [7] A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer
    Takayuki Yoshino
    Kentaro Yamazaki
    Kensei Yamaguchi
    Toshihiko Doi
    Narikazu Boku
    Nozomu Machida
    Yusuke Onozawa
    Masako Asayama
    Tadahiro Fujino
    Atsushi Ohtsu
    Investigational New Drugs, 2013, 31 : 910 - 917
  • [8] Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study
    Li, Jin
    Xu, Ruihua
    Qin, Shukui
    Liu, Tianshu
    Pan, Hongming
    Xu, Jianming
    Bi, Feng
    Lim, Robert
    Zhang, Suzhan
    Ba, Yi
    Bai, Yuxian
    Fan, Nanfeng
    Tsuji, Akihito
    Yeh, Kun-Huei
    Ma, Brigette
    Wei, Vivian
    Shi, Dongmei
    Magherini, Emmanuelle
    Shen, Lin
    FUTURE ONCOLOGY, 2018, 14 (20) : 2030 - 2043
  • [9] Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer
    Denda, Tadamichi
    Sakai, Daisuke
    Hamaguchi, Tetsuya
    Sugimoto, Naotoshi
    Ura, Takashi
    Yamazaki, Kentaro
    Fujii, Hirofumi
    Kajiwara, Takeshi
    Nakajima, Takako Eguchi
    Takahashi, Shin
    Otsu, Satoshi
    Komatsu, Yoshito
    Nagashima, Fumio
    Moriwaki, Toshikazu
    Esaki, Taito
    Sato, Takeo
    Itabashi, Michio
    Oki, Eiji
    Sasaki, Toru
    Sunaga, Yoshinori
    Ziti-Ljajic, Samira
    Brillac, Claire
    Yoshino, Takayuki
    CANCER SCIENCE, 2019, 110 (03) : 1032 - 1043
  • [10] Prognostic Impact of KRAS Mutational Status in Patients with Colorectal Cancer Liver Metastases Differs According to the Location of the Primary Tumor
    Amini, Neda
    Margonis, Georgios Antonios
    Kreis, Martin E.
    Poultsides, George A.
    Sasaki, Kazunari
    Wagner, Doris
    Pikoulis, Emmanouil
    Weiss, Matthew J.
    Wolfgang, Christopher L.
    Safar, Bashar
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2019, 229 (04) : S69 - S70
12345